ストックスクリーナーアプリを入手
15.74
2.80%
-0.525
前日終値:
$16.27
開ける：
$16.04
24時間の取引高:
71,845
Relative Volume:
0.05
時価総額：
$2.71B
収益：
$890.53M
当期純損益:
$30.57M
株価収益率:
-17.11
EPS:
-0.92
ネットキャッシュフロー:
$80.53M
1週間 パフォーマンス:
-7.08%
1か月 パフォーマンス:
+7.14%
6か月 パフォーマンス:
+3.56%
1年 パフォーマンス:
-29.56%
1日の値動き範囲:
$15.66
$16.13
1週間の範囲:
$15.66
$17.30
52週間の値動き範囲:
$14.15
$32.59
Acadia Pharmaceuticals Inc Stock (ACAD) Company Profile
名前
Acadia Pharmaceuticals Inc
セクター
電話
858-558-2871
住所
12830 EL CAMINO REAL, SAN DIEGO
ACAD を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
| ACAD | 15.75 | 2.71B | 890.53M | 30.57M | 80.53M | -0.92 |
| VRTX | 448.13 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 742.12 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 590.43 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 249.32 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 102.27 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Acadia Pharmaceuticals Inc Stock (ACAD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-03-12 | ダウングレード | Mizuho | Buy → Neutral |
| 2024-03-12 | 繰り返されました | Needham | Buy |
| 2024-01-30 | 開始されました | Robert W. Baird | Outperform |
| 2024-01-24 | アップグレード | Needham | Hold → Buy |
| 2023-12-19 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2023-12-14 | ダウングレード | Deutsche Bank | Buy → Hold |
| 2023-12-13 | 開始されました | Citigroup | Buy |
| 2023-12-12 | 開始されました | Deutsche Bank | Buy |
| 2023-11-06 | アップグレード | Mizuho | Neutral → Buy |
| 2023-10-17 | 開始されました | UBS | Buy |
| 2023-10-10 | アップグレード | JP Morgan | Neutral → Overweight |
| 2023-01-03 | アップグレード | Guggenheim | Neutral → Buy |
| 2022-11-04 | ダウングレード | Goldman | Neutral → Sell |
| 2022-11-01 | 開始されました | Loop Capital | Hold |
| 2022-08-08 | ダウングレード | Citigroup | Buy → Neutral |
| 2022-08-05 | ダウングレード | Citigroup | Buy → Neutral |
| 2022-06-21 | ダウングレード | Jefferies | Buy → Underperform |
| 2022-06-16 | アップグレード | Jefferies | Hold → Buy |
| 2022-03-16 | アップグレード | Canaccord Genuity | Hold → Buy |
| 2022-02-09 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2022-01-05 | アップグレード | Citigroup | Neutral → Buy |
| 2021-12-21 | ダウングレード | Guggenheim | Buy → Neutral |
| 2021-11-01 | アップグレード | Guggenheim | Neutral → Buy |
| 2021-10-14 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-23 | 再開されました | Needham | Hold |
| 2021-06-10 | 開始されました | Berenberg | Hold |
| 2021-04-07 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2021-04-06 | ダウングレード | Canaccord Genuity | Buy → Hold |
| 2021-04-06 | ダウングレード | Goldman | Buy → Neutral |
| 2021-04-06 | ダウングレード | Jefferies | Buy → Hold |
| 2021-04-06 | ダウングレード | Mizuho | Buy → Neutral |
| 2021-04-05 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2021-03-10 | ダウングレード | BofA Securities | Buy → Neutral |
| 2021-03-09 | ダウングレード | Citigroup | Buy → Neutral |
| 2021-03-09 | ダウングレード | Guggenheim | Buy → Neutral |
| 2021-03-09 | 繰り返されました | H.C. Wainwright | Buy |
| 2021-03-09 | ダウングレード | Raymond James | Strong Buy → Outperform |
| 2021-03-09 | ダウングレード | Stifel | Buy → Hold |
| 2020-12-16 | 開始されました | Mizuho | Buy |
| 2020-11-16 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2020-08-25 | 開始されました | Raymond James | Outperform |
| 2020-08-20 | 開始されました | Morgan Stanley | Overweight |
| 2020-07-07 | アップグレード | Stifel | Hold → Buy |
| 2020-04-16 | 開始されました | Jefferies | Buy |
| 2020-03-31 | アップグレード | Goldman | Neutral → Buy |
| 2020-03-06 | 開始されました | Citigroup | Buy |
| 2019-12-16 | 開始されました | Guggenheim | Buy |
| 2019-10-24 | 開始されました | Oppenheimer | Perform |
| 2019-10-01 | 開始されました | RBC Capital Mkts | Outperform |
| 2019-09-13 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2019-09-10 | アップグレード | Canaccord Genuity | Hold → Buy |
| 2019-07-23 | 繰り返されました | Needham | Buy |
| 2018-12-10 | 開始されました | Canaccord Genuity | Hold |
| 2018-09-21 | アップグレード | Piper Jaffray | Neutral → Overweight |
| 2018-08-09 | 繰り返されました | Stifel | Hold |
| 2018-08-07 | 開始されました | Stifel | Hold |
| 2018-08-06 | ダウングレード | Piper Jaffray | Overweight → Neutral |
| 2017-10-06 | 再開されました | Goldman | Neutral |
すべてを表示
Acadia Pharmaceuticals Inc (ACAD) 最新ニュース
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Stake Decreased by Connor Clark & Lunn Investment Management Ltd. - MarketBeat
When (ACAD) Moves Investors should Listen - Stock Traders Daily
Acadia Pharmaceuticals announces executive shakeup - Investing.com
Acadia Pharmaceuticals' Operating Chief Involuntarily Terminated Without Cause - MarketWatch
Acadia Pharmaceuticals Announces Leadership Change Amid COO Departure - TipRanks
Acadia Pharma (ACAD) Chief Operating Officer to be Involuntarily Terminated Without Cause - StreetInsider.com
Acadia Pharma ticks lower amid Deutsche Bank downgrade after surge on patent win - MSN
FY2027 Earnings Forecast for ACAD Issued By Leerink Partnrs - MarketBeat
Acadia's Q3 Earnings Beat, Nuplazid & Daybue Drive Revenue Growth - MSN
Acadia Pharmaceuticals CFO sells shares worth $172,453 - Investing.com India
Acadia Pharmaceuticals CFO sells shares worth $172,453 By Investing.com - Investing.com Canada
Acadia Pharmaceuticals' COO sells $173,630 in stock By Investing.com - Investing.com Canada
FY2024 Earnings Estimate for ACAD Issued By Leerink Partnrs - MarketBeat
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Sees Large Growth in Short Interest - MarketBeat
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Holdings Lowered by GSA Capital Partners LLP - MarketBeat
Acadia Pharmaceuticals Grants Stock Options, RSUs to 23 New Employees in Growth Push | ACAD Stock News - StockTitan
ACADIA Pharmaceuticals' SWOT analysis: mixed results for CNS drug stock By Investing.com - Investing.com Canada
ACADIA Pharmaceuticals' SWOT analysis: mixed results for CNS drug stock - Investing.com
Analysts Set ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Target Price at $25.56 - MarketBeat
Here's Why Acadia Pharmaceuticals (ACAD) is a Strong Momentum Stock - Yahoo Finance
US Bancorp DE Has $507,000 Stock Holdings in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - MarketBeat
Acadia Pharmaceuticals: Proving The Naysayers Wrong (NASDAQ:ACAD) - Seeking Alpha
What is Leerink Partnrs' Forecast for ACAD FY2026 Earnings? - MarketBeat
FY2024 Earnings Estimate for ACAD Issued By HC Wainwright - MarketBeat
Acadia Pharmaceuticals (ACAD) Beats Q3 Earnings and Revenue Estimates - MSN
ACADIA Pharmaceuticals Inc. Just Recorded A 43% EPS Beat: Here's What Analysts Are Forecasting Next - Yahoo Finance
Acadia Pharmaceuticals Breaks Above 200-Day Moving AverageBullish for ACAD - Nasdaq
Acadia Pharmaceuticals price target lowered to $32 from $33 at Canaccord - TipRanks
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Q3 2024 Earnings Call Transcript - Insider Monkey
Equities Analysts Issue Forecasts for ACAD FY2027 Earnings - MarketBeat
HC Wainwright Issues Pessimistic Estimate for ACAD Earnings - MarketBeat
ACADIA Pharmaceuticals Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions - Simply Wall St
ACADIA Pharmaceuticals Third Quarter 2024 Earnings: EPS Beats Expectations - Yahoo Finance
ACADIA Pharmaceuticals Inc. (ACAD) Quarterly 10-Q Report - Quartzy
ACADIA Pharmaceuticals (NASDAQ:ACAD) Issues Earnings Results - MarketBeat
Acadia Pharmaceuticals participates in a conference call with JPMorgan - TipRanks
ACADIA Pharmaceuticals (NASDAQ:ACAD) Given Buy Rating at HC Wainwright - MarketBeat
ACADIA Pharmaceuticals (NASDAQ:ACAD) Earns Buy Rating from Needham & Company LLC - MarketBeat
Acadia Pharma Q3 2024 Earnings Preview - MSN
ACADIA Pharmaceuticals Inc (ACAD) Q3 2024 Earnings Call Highlights: Strong Sales Growth and ... By GuruFocus - Investing.com Canada
ACADIA Pharmaceuticals Inc (ACAD) Q3 2024 Earnings Call Highligh - GuruFocus.com
ACADIA Pharmaceuticals Inc (ACAD) Q3 2024 Earnings Call Highlights: Strong Sales Growth and ... - Yahoo Finance
Acadia: Q3 Earnings Snapshot - Houston Chronicle
Acadia Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operating Overview - BioSpace
Acadia Pharmaceuticals Sees Revenue Growth and Strategic Advances - TipRanks
Acadia Pharmaceuticals reports Q3 EPS , consensus 14c - TipRanks
ACADIA Pharmaceuticals Q3 2024 Earnings: EPS of $0.20 Beats Esti - GuruFocus.com
Acadia Pharma Sells Voucher for Speedier FDA Drug Review for $150M - MedCity News
Acadia Pharma (ACAD) Tops Q3 EPS by 6c ; Offers Guidance - StreetInsider.com
Acadia Pharma sells priority review voucher for $150 million | Pharmaceutical | The Pharmaletter - The Pharma Letter
Acadia sells speedy drug review voucher for $150M - BioPharma Dive
Acadia Pharmaceuticals Inc (ACAD) 財務データ
収益
当期純利益
現金流量
EPS
0.42%
0.16%
大文字化:
|
ボリューム (24 時間):